

# Uflex: Is the worst over for this company?

Healthy volume and margin recovery seen in flexible and aseptic packaging businesses. Better numbers expected in the upcoming quarters

KHUSHBOO RAI | NOVEMBER 17, 2023 / 11:15 AM IST

#### WATCH WEBINAR







Pro Masters Virtual: Watch 'Inter-Market Analysis - How Macro Factors Impact Market Direction?' with Rohit Srivastava

WATCH MORE

# PRO PANORAMA

#### Moneycontrol Pro Panorama | Will the good times in realty continue?

In this edition of Moneycontrol Pro Panorama: RBI's credit deployment data add to existing anxiety, FMCG companies may have over...

READ NOW

# PRO WEEKENDER

#### Moneycontrol Pro Weekender: Ode to consumption

Can consumption continue to support growth? We'll soon know how strong festive demand has been

**READ NOW** 

Uflex is trodding the path of innovation in the fast-paced packaging sector, adding new products every year

#### You can gift this story to any non-subscriber #



# ighlights

Strong pick-up in flexible packaging volumes

- · Global demand for packaging films to improve
- · Aseptic capacity additions to boost margin growth

#### **INTERVIEW SERIES**





Watch: Moneycontrol Pro's The Consistent Compounders Show -Episode 3

WATCH MORE

- Captive raw material projects to further boost margins
- Valuation reasonable on promising outlook

Things have started looking up for

#### Uflex Ltd (CMP: Rs 439; M Cap: Rs 3,160 crore; Rating: Overweight),

India's largest multinational in flexible packaging.

After suffering huge loss due to the Nigerian currency devaluation in the previous quarter, the September quarter saw a healthy volume recovery and a sharp growth in margins, sequentially. The company recorded a net profit of Rs 63 crore in Q2 FY24 against a net loss of Rs 416 crore in Q1 FY24.

The domestic packaging films market remains robust, while the global business will start seeing an upturn in the coming quarters.

# **QUARTERLY SNAPSHOT**

(In Rs. Cr.)	Q2 FY24	Q2 FY23	YoY	Q1FY24	QoQ
Net Revenue	3297.5	3737.6	-11.77%	3219.92	2%
EBITDA	405.89	502	-19%	304	34%
PBT (before Exceptional items)	109.8	242.2	-55%	8.63	1172%
Reported PBT (after exchange loss)*	109.8	242.2	-55%	-373	NM
Reported PAT*	63.3	190.7	-67%	-416	NM
EBITDA Margin (%)	12.3%	13.4%	(112 bps)	9.4%	+290 bps
PAT Margin (%)	1.9%	5.1%	(318 bps)	NM	NM

Note: \* After forex loss of Rs. 382 crore in Q1, NM: Not Meaningful Source: Company & Moneycontrol Research









## **FINANCIAL SNAPSHOT**

(In Rs. Cr.)	H1 FY24	H1 FY23	YoY
Sales Volume (MTPA in 000)	293999	304548	-3.5%
Net Revenue	6517	7895	-17.4%
EBITDA	710	1218	-42%
Reported PAT*	-353	565	NM

Note: \* After forex loss of Rs. 382 crore in Q1; NM: Not Meaningful











#### RELATED STORIES



China-Iran-Russia nexus might see the Middle East emerge as a crucial fourth



Nifty FY24 earnings set to outpace FY23 despite mixed results

#### Q2 FY24 Update:

#### Healthy volume growth, momentum to continue

Although the performance of the packaging film business was flat on a YoY basis, the shift in focus towards regaining volumes aided healthy sequential growth in Q2 (up 6.6 percent).

The flevible and liquid nackaging business



Weekly Tactical Pick: All negatives are priced in for this stock continues to perform well on the back of strong demand from the FMCG segment. The quarter saw a 21 percent QoQ volume growth.

The management strives to increase utilisation across businesses and targets a sequential volume

growth in the 7-8 percent range in the packaging film. It hopes to maintain growth in the flexible packaging business in the second half of the current fiscal (H2 FY24).

The aseptic packaging continued its strong run, backed by orders from new customers. **The** de-bottlenecking of the aseptic packaging plant will help in expanding the capacity to 12 billions pack by September 2024 end from the current 7 billion packs.

#### Sharp recovery in margins

Globally, European margins remain below expectations, while America saw higher margins in Q2. The trend is expected to continue.

In the domestic market, BoPP (biaxially oriented polypropylene) saw healthy margin recovery. However, given the lean quarter for liquid packaging, aseptic packaging margins were down and will likely improve after December.

That said, the aseptic business looks very promising with higher margin contribution and capacity addition will likely aid top-line growth in FY24.

The consolidated EBITDA margin of 12.3 percent in Q2 was well within the guidance. It increased by 290 basis points QoQ, primarily driven by a better domestic performance across businesses.

In the near-term, the management targets an EBITDA margin in the 12-12.5 percent range by Q3 FY24 and 13.5 percent by Q4 FY24.

(In Rs. Cr.)	Q2 FY24	Q2 FY23	YoY	Q1FY24	QoQ
Net Revenue	3297.5	3737.6	-11.77%	3219.92	2%
EBITDA	405.89	502	-19%	304	34%
PBT (before Exceptional items)	109.8	242.2	-55%	8.63	1172%
Reported PBT (after exchange loss)*	109.8	242.2	-55%	-373	NM
Reported PAT*	63.3	190.7	-67%	-416	NM
EBITDA Margin (%)	12.3%	13.4%	(112 bps)	9.4%	+290 bp
PAT Margin (%)	1.9%	5.1%	(318 bps)	NM	NM

#### **Outlook and valuation**

Uflex is a revered global leader with a large array of products, coupled with a diversified packaging value chain. The company is trodding the path of innovation in the fast-paced packaging sector, adding new products every year.

The European market remains sluggish, while in India overcapacity is driving pricing and

margins down. Barring the near-term uncertainty, we believe that Uflex's well-integrated business model will drive better performances on a consolidated basis, going forward.

The aseptic business looks very promising with higher margin contribution (margins in the high-teens range) and will aid margin growth in the H2 FY24. The Asepto (liquid packaging brand) expansion was delayed due to equipment shortage and will be commissioned by the Sep-Oct period of 2024.

Moreover, captive projects to manufacture PET chips (capacity of 140k tonnes per annum) for BoPET films (biaxially oriented polyethylene terephthalate, a polyester film made from stretched polyethylene terephthalate (PET) is on track and is likely to be operational by FY24 end. This will enhance packaging film margins by around 1.5 percent in FY25.

On a consolidated basis, total revenue is expected to decline by around 10 percent and the target EBITDA margin is in the 11.5 percent range in FY24.

The sector as a whole remains undervalued at a multiple of 4-5 times EV/EBITDA ratio in the past one year. The revival in demand and margins could lead to the sector's re-rerating.

On the valuation front, Uflex is trading at 5.0 times EV/EBITDA and 6.6 times P/E on FY25e earnings. This is reasonable, considering the potential earnings growth.

We advise investors to consider it as a long-term buying opportunity.

#### **VALUATION SUMMARY** (Rs. Cr.) **FY23** FY24e FY25e Net operating revenue 14,663 13,196 14,120 12% -10% 7% % growth y-o-y **EBITDA** 2,068 1,518 1,836 EBITDA margin (%) 14% 12% 13% Net Profit 481 264 494 Net Profit margin (%) 3.3% 2.0% 3.5% **Current Market capitalisation** 3,260 Price- to-earnings ratio (x) 6.8 12.4 6.6 EV/EBITDA(x) 3.7 5.9 5.0 7% ROE 4% 6% Source: Company & Moneycontrol Research f 😵 💿 🥑 🛅 🕖


For more research articles, visit our Moneycontrol Research page

KHUSHBOO RAI

### Tags:

#Aseptic Packaging #MCPro #Moneycontrol Research #stock recommendation
#Uflex Ltd

Discover the latest <u>business news</u>, <u>Sensex</u>, and <u>Nifty</u> updates. Obtain <u>Personal Finance</u> insights, tax queries, and expert opinions on <u>Moneycontrol</u> or download the <u>Moneycontrol App</u> to stay updated!



Copyright © e-Eighteen.com Ltd. All rights reserved. Reproduction of news articles, photos, videos or any other content in whole or in part in any form or medium without express writtern permission of moneycontrol.com is prohibited.